In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leadership

Set Alert for Leadership

Aetion: Sealing The Deal With Payers On Real-World Research

As biopharma’s embrace of real-world evidence (RWE) gathers speed, In Vivo looks at one company that is using a mix of prestigious academic, government and non-profit partners to build a credible foundation for acceptance of this research tool in the wider commercial space. 

Innovation Strategy Reimbursement
Advertisement

Latest From Leadership

Room At The Top? The Case For A Chief Value Officer

As pharmaceutical pricing and market access functions face increasing scrutiny from stakeholders, it is time for C-suite leaders to focus more on value creation, communication, and governance in order to articulate the value of not only of their therapies but also industry contribution at-large.

Leadership Strategy

Execs On the Move, Oct 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

VistaGen Stocks Neuropsychiatry Pipeline And Takes Aim At Depression Market

Shawn Singh, CEO of VistaGen, a growing Silicon Valley-based biotech focused on psychiatry and neurological drug development, outlines the company’s strategy for getting to market in the US and expanding its pipeline into new areas.

Leadership Research and Development Strategies

Japan’s Healios Eyes First Approvals As It Progresses Regenerative Therapies

Healios, a Japanese regenerative medicine bioventure, expects to continue benefiting from a supportive regulatory environment in Japan as it progresses three clinical assets toward approval in the next few years, says CEO Dr. Hardy Kagimoto in an exclusive interview.

Asia Pacific Regenerative Medicine

Execs On The Move, Sept 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical

Gene Therapy: Spark Charts A Course From Science To Payer And Patient Satisfaction

Gene therapy’s promise depends on the ecosystem now being built to deliver real product to patients – safely and at quantities that match the soaring expectations fed by the curative potential of the science. To assess the state of play, In Vivo talks to the man who leads the team responsible for bringing forward the first US-approved gene therapy to treat an incurable, inherited genetic condition: John Furey, chief operating officer of Spark Therapeutics

C-Suite Speaks Leadership
See All
UsernamePublicRestriction

Register